Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
'Backward and upward and tilted': Spaceflight causes astronauts' brains to shift inside their skulls - 2Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- 3Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
- 4Roman around the Christmas tree | Space photo of the day for Dec. 25, 2025
- 5Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- Vote in favor of Your Number one kind of pie
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- 4 African Vacationer Locations
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- Key Business Regulations to Consider While Arranging Your Independent venture
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
